Company news

Voyager Therapeutics, Inc. news in 2026

Voyager Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Voyager Announces CEO Succession Plan, Appoints Robin Swartz President

October 21, 2026

Voyager Technologies, Inc. Completes $402.5 Million Convertible Senior Notes Offering

September 28, 2026

Voyager Technologies, Inc. Announces Proposed Convertible Senior Notes Offering

September 22, 2026

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

July 13, 2026

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

June 10, 2026

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

June 1, 2026

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

May 13, 2026

Voyager Reports First Quarter 2026 Financial and Operating Results

May 7, 2026

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

April 27, 2026

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

March 8, 2026

Voyager to Present at Upcoming Investor Conferences

February 9, 2026

Decks in 2026